Drug Index

Mechanism :

Binds reversibly to nonstructural protein 3 (NS 3) serine protease and inhibits replication of the hepatitis C virus. Considered a direct-acting antiviral treatment for HCV, also called a specifically targeted antiviral therapy for HCV (STAT-C).

Indication :

  • Chronic hepatitis C genotype 1 infection in combination with peginterferon alfa and ribavirin.

Dosing :

Pediatric safety and efficacy not established.
The recommended dose is 1125 mg (three 375 mg tablets) taken orally twice daily (10-14 hours apart) with food for 12 weeks.

Adverse Effect :

Rash, fatigue, pruritus, nausea, anemia, diarrhea, vomiting, hemorrhoids, anorectal discomfort, dysgeusia

Interaction :

Digoxin: Telaprevir will increase the level or effect of digoxin by P-glycoprotein (MDR1) efflux transporter.
Ivosidenib: Ivosidenib and telaprevir both increase QTc interval.

Hepatic Dose :

Mild hepatic impairment: No dose adjustment recommended.
Moderate to severe hepatic impairment: Administration of the drug is not recommended.
09/28/2020 07:50:51 Telaprevir
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0